文献速递外周动脉疾病

Omniflow II生物合成移植物早期移植物、肢体与死亡结局

Early Graft, Limb and Mortality Outcomes from the Omniflow II Bio-Synthetic Graft.
PubMed 文献 · Ann Vasc Surg · 2021-08-28

单中心回顾性研究纳入24例Omniflow II生物合成移植物,评估1–3年原发通畅率、肢体存活率与患者生存率。1年与3年原发通畅率分别为54.2%和37.5%,肢体存活概率分别为75%和70.8%,均明显低于既往对照研究;1年与3年生存概率分别为91.7%和87.5%。作者认为需进一步开展随机对照试验。

要点

  • 1年与3年原发通畅率分别为54.2%和37.5%,低于既往对照研究
  • 1年与3年肢体存活概率分别为75%和70.8%
  • 1年与3年患者生存概率分别为91.7%和87.5%,表现较好

核心结论

  • Omniflow II移植物的原发通畅率与保肢率明显低于同类研究,患者生存率表现较好。
  • 作者认为需要开展随机对照试验进一步验证。

研究设计与样本

  • 单中心回顾性研究,纳入2015年9月23日至2018年4月5日植入的Omniflow II移植物,涵盖所有解剖部位。
  • 共24例患者、24条移植物,平均年龄71.4 ± 11.7岁,女性5例、男性19例。

主要发现

  • 最常见指征为静息痛/间歇性跛行(N = 8),其次为移植物闭塞(N = 6)。
  • 最常见术式为股腘旁路(N = 13)和股远端旁路(N = 5)。
  • Kaplan-Meier分析显示1年与3年原发通畅率分别为54.2%和37.5%。
  • 1年与3年肢体存活概率分别为75%和70.8%。
  • 1年与3年生存概率分别为91.7%和87.5%,平均随访296天(范围95–451天)。

关键数值与推荐

  • 原发通畅定义:无干预下的通畅。
  • 主要结局指标为患者总生存及时间、原发通畅率、1年与3年肢体存活率。

临床怎么用

  • 可将Omniflow II用于需避免自体移植物或存在感染风险的旁路病例,但需预期其通畅率与保肢率可能偏低。
  • 术后应加强移植物通畅性与肢体存活的监测随访。

局限性

  • 单中心回顾性设计,样本量仅24例。
  • 随访时间较短,平均296天(范围95–451天)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Omniflow II biosynthetic grafts are a commonly used alternative to autologous grafts in vascular bypass procedures. They are chosen for their purported resilience to infection, often in instances of existing graft failure or infection. We examined the short term, 1-3 year outcomes of Omniflow grafts in terms of patency, limb survival and mortality in a sample of 24 individuals. METHODS: This is a single centred retrospective study of Omniflow II grafts implanted between September 23, 2015 and April 05, 2018 in our department. It includes grafts in all anatomical locations. Primary outcome measures were overall patient survival and time to this, primary graft patency (patency with no intervention) and then limb survival at 1 and 3 years. Kaplan-Meier survival analysis was plotted for the 3 primary outcome measures. RESULTS: A total of 24 grafts from 24 individuals were included with mean age 71.4 ± 11.7. We included 5 female and 19 male patients. The commonest indication was rest pain/claudication (N = 8) followed by graft occlusion (N = 6). Femoro-popliteal bypass (N = 13) and Femoro-distal bypass (N = 5) were the commonest procedures. Kaplan-Meier survival analysis demonstrated that 1 and 3-year primary patency rates were 54.2% and 37.5% respectively with Limb survival probability of 75% at 1 year and 70.8% at 3 years. These rates were all considerably lower than those found in previous comparative studies. Mortality however, compared favourably with 1 and 3-year survival probability 91.7% and 87.5% on average 296 days (range 95-451 days) after graft implantation. CONCLUSIONS: We found that rates of primary patency and limb salvage for this graft type were markedly lower than in comparable studies. Further work in the form of a RCT is indicated.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Evans W, Buchanan J, Goel R, et al. Early Graft, Limb and Mortality Outcomes from the Omniflow II Bio-Synthetic Graft. Ann Vasc Surg. 2021. PMID: 34464727. doi:10.1016/j.avsg.2021.06.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。